Table 3

Efficacy of temozolomide in brain tumor xenograft models

TumorTreatmentNo. in groupAverage week tumor achieved 4× initial tumor volume (1 SD)Tumor growth delay (weeks)Adjusted PaNo. of PRsNo. of CRsMCRbTime to reach nadir (weeks)cTime to recover to initial tumor volume (weeks)d
D283Control55.3 ± 0.500
667>12>6.70.00134039
D283cControl62.6 ± 0.900
6676.8 ± 0.44.20.0042012
D283cControl54 ± 100
6678.4 ± 1.54.40.0053025
SJ-BT27Control63 ± 1.1000
667>12>90.0010772>12
SJ-BT29Control63.6 ± 0.500
6646.4 ± 1.82.80.02000NRdNR
SJ-GBM2Control72.4 ± 0.500
6678.7 ± 0.65.30.00202045
SJ-GBM2cControl73.5 ± 100
66710.5 ± 2.170.00131049
  • a Ps were obtained using exact log-rank tests (with Bonferroni correction procedure). Ps compare tumor failure times among treatment groups and respective control group.

  • b Number of CRs maintained through week 12.

  • c Replicate studies.

  • d NR, no regression.